Pub Date : 2026-02-05DOI: 10.1016/j.endien.2026.501691
Josefa Rojas Villegas, Lourdes Garcia Garcia-Doncel, Maria Angeles Santos Mata, Yolanda Quirós López, Isabel Morón Rubio
{"title":"Study of the prevalence of obesity and sedentary lifestyle among school-aged children in the Health Area of Jerez, Northwest Coast and Sierra de Cádiz.","authors":"Josefa Rojas Villegas, Lourdes Garcia Garcia-Doncel, Maria Angeles Santos Mata, Yolanda Quirós López, Isabel Morón Rubio","doi":"10.1016/j.endien.2026.501691","DOIUrl":"https://doi.org/10.1016/j.endien.2026.501691","url":null,"abstract":"","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":" ","pages":"501691"},"PeriodicalIF":1.8,"publicationDate":"2026-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146133378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-05DOI: 10.1016/j.endien.2026.501688
Lucía Estévez Asensio, Esther Delgado García, Marina Gómez Andrés, María Samaniego Montoro, Antonia Maniega Rubio, Carmen Fernández Rodríguez, Ruth González Collantes, María José Bartolomé Albistegui, Marta Alonso Mesonero, Ana Belén Casas Marcos, Daniel A de Luis Román, Emilia Gómez Hoyos
Introduction: Gender Affirming Hormone Therapy (GAHT) improves psychological well-being and certain quality-of-life parameters. Nevertheless, the satisfaction perceived by individuals undergoing this treatment remains unclear. The aim of this study was to assess such satisfaction using the Spanish adaptation of the received treatment satisfaction scale (CRES-4).
Material and methods: Cross-sectional observational study among transgender individuals who had been receiving GAHT for >1 year and had not undergone genital reassignment surgery. Participants were recruited from a Transgender Medicine Unit between January 2014 and January 2023. Demographic and clinical data were collected, along with responses to the CRES-4 scale. Statistical analysis performed using SPSS-V-23.
Results: Out of the 83 subjects included, 52 (62.7%) were identified as transgender men and 31 (37.3%) as transgender women. The median age at initiation of GAHT was 19 [17-25] years, with a median treatment duration of 3 [1.75-4] years at the time of evaluation. 95% of participants reported being satisfied with GAHT and 75% noted an improvement in the "perceived problem solution" domain. Emotional well-being improved markedly, with 68% reporting an acceptable emotional state after GAHT, compared to 9% before starting treatment. Satisfaction was not significantly associated with treatment duration, psychological comorbidity, age at initiation, non-genital gender-affirming surgeries or type of hormone therapy (feminizing vs. masculinizing).
Conclusions: Most transgender individuals reported high levels of satisfaction with GAHT when provided as part of comprehensive biopsychosocial care. The therapy improved emotional well-being and enhanced perceptions of problem resolution.
{"title":"Satisfaction associated with gender-affirming hormone therapy.","authors":"Lucía Estévez Asensio, Esther Delgado García, Marina Gómez Andrés, María Samaniego Montoro, Antonia Maniega Rubio, Carmen Fernández Rodríguez, Ruth González Collantes, María José Bartolomé Albistegui, Marta Alonso Mesonero, Ana Belén Casas Marcos, Daniel A de Luis Román, Emilia Gómez Hoyos","doi":"10.1016/j.endien.2026.501688","DOIUrl":"https://doi.org/10.1016/j.endien.2026.501688","url":null,"abstract":"<p><strong>Introduction: </strong>Gender Affirming Hormone Therapy (GAHT) improves psychological well-being and certain quality-of-life parameters. Nevertheless, the satisfaction perceived by individuals undergoing this treatment remains unclear. The aim of this study was to assess such satisfaction using the Spanish adaptation of the received treatment satisfaction scale (CRES-4).</p><p><strong>Material and methods: </strong>Cross-sectional observational study among transgender individuals who had been receiving GAHT for >1 year and had not undergone genital reassignment surgery. Participants were recruited from a Transgender Medicine Unit between January 2014 and January 2023. Demographic and clinical data were collected, along with responses to the CRES-4 scale. Statistical analysis performed using SPSS-V-23.</p><p><strong>Results: </strong>Out of the 83 subjects included, 52 (62.7%) were identified as transgender men and 31 (37.3%) as transgender women. The median age at initiation of GAHT was 19 [17-25] years, with a median treatment duration of 3 [1.75-4] years at the time of evaluation. 95% of participants reported being satisfied with GAHT and 75% noted an improvement in the \"perceived problem solution\" domain. Emotional well-being improved markedly, with 68% reporting an acceptable emotional state after GAHT, compared to 9% before starting treatment. Satisfaction was not significantly associated with treatment duration, psychological comorbidity, age at initiation, non-genital gender-affirming surgeries or type of hormone therapy (feminizing vs. masculinizing).</p><p><strong>Conclusions: </strong>Most transgender individuals reported high levels of satisfaction with GAHT when provided as part of comprehensive biopsychosocial care. The therapy improved emotional well-being and enhanced perceptions of problem resolution.</p>","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":" ","pages":"501688"},"PeriodicalIF":1.8,"publicationDate":"2026-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146133326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-05DOI: 10.1016/j.endien.2026.501689
Isabella Mattei, María Calatayud Gutiérrez, Carla Jimena Santiváñez Pérez
{"title":"Refractory hypothyroidism and treatment with subcutaneous levothyroxine: a case report.","authors":"Isabella Mattei, María Calatayud Gutiérrez, Carla Jimena Santiváñez Pérez","doi":"10.1016/j.endien.2026.501689","DOIUrl":"https://doi.org/10.1016/j.endien.2026.501689","url":null,"abstract":"","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":" ","pages":"501689"},"PeriodicalIF":1.8,"publicationDate":"2026-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146133315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-05DOI: 10.1016/j.endien.2026.501713
Javier Lago Garma, Cristina Gil Mouce, Nazareth Rodríguez Novo, Olaia Díaz Trastoy, Alicia Santamaría Nieto, Patricia Pérez Castro, Carmen Díaz Ortega, Eva Fernández Rodríguez, Regina Palmeiro Carballeira, Iria Pinal Osorio, Alma Prieto Tenreiro, Paula Sánchez Sobrino, Cristina Tejera Pérez, Francisco Pita Gutiérrez, Rocío Villar Taibo, Alfonso Vidal Casariego
Introduction: Type 2 diabetes mellitus (T2DM) significantly impacts the patients' quality of life due to chronic complications and associated comorbidities. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated benefits in glycemic control. This study evaluates the effect of oral semaglutide on quality of life, metabolic parameters, and treatment adherence of T2DM patients.
Patients and methods: We conducted a multicenter prospective observational study Galicia (Spain). A total of 43 adult T2DM patients on oral semaglutide were evaluated at baseline and 3-6 months later using validated questionnaires (DTSQ and EuroQol), anthropometric measures, and metabolic parameters. Changes in quality of life, HbA1c, weight, lipid profile, and insulin dose were analyzed.
Results: Oral semaglutide significantly improved quality of life according to the visual analog scale (from 62.8 to 72.6 points; p < 0.001) and DTSQ questionnaire (from 28.2 to 33.0 points; p < 0.001). Significant reductions were observed in HbA1c (8.3% to 7.2%; p < 0.001) and body weight (-4.9%; p = 0.018). The most common adverse effects were nausea and vomiting, reported by 39.5% of patients, with no impact on the overall quality of life.
Conclusion: Oral semaglutide significantly improves quality of life and metabolic parameters in T2DM patients, with good tolerance and low discontinuation rates. These findings support its utility in the comprehensive management of T2DM.
{"title":"Impact of oral semaglutide on quality of life and metabolic parameters in patients with type 2 diabetes mellitus: A multicenter observational study.","authors":"Javier Lago Garma, Cristina Gil Mouce, Nazareth Rodríguez Novo, Olaia Díaz Trastoy, Alicia Santamaría Nieto, Patricia Pérez Castro, Carmen Díaz Ortega, Eva Fernández Rodríguez, Regina Palmeiro Carballeira, Iria Pinal Osorio, Alma Prieto Tenreiro, Paula Sánchez Sobrino, Cristina Tejera Pérez, Francisco Pita Gutiérrez, Rocío Villar Taibo, Alfonso Vidal Casariego","doi":"10.1016/j.endien.2026.501713","DOIUrl":"https://doi.org/10.1016/j.endien.2026.501713","url":null,"abstract":"<p><strong>Introduction: </strong>Type 2 diabetes mellitus (T2DM) significantly impacts the patients' quality of life due to chronic complications and associated comorbidities. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated benefits in glycemic control. This study evaluates the effect of oral semaglutide on quality of life, metabolic parameters, and treatment adherence of T2DM patients.</p><p><strong>Patients and methods: </strong>We conducted a multicenter prospective observational study Galicia (Spain). A total of 43 adult T2DM patients on oral semaglutide were evaluated at baseline and 3-6 months later using validated questionnaires (DTSQ and EuroQol), anthropometric measures, and metabolic parameters. Changes in quality of life, HbA1c, weight, lipid profile, and insulin dose were analyzed.</p><p><strong>Results: </strong>Oral semaglutide significantly improved quality of life according to the visual analog scale (from 62.8 to 72.6 points; p < 0.001) and DTSQ questionnaire (from 28.2 to 33.0 points; p < 0.001). Significant reductions were observed in HbA1c (8.3% to 7.2%; p < 0.001) and body weight (-4.9%; p = 0.018). The most common adverse effects were nausea and vomiting, reported by 39.5% of patients, with no impact on the overall quality of life.</p><p><strong>Conclusion: </strong>Oral semaglutide significantly improves quality of life and metabolic parameters in T2DM patients, with good tolerance and low discontinuation rates. These findings support its utility in the comprehensive management of T2DM.</p>","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":" ","pages":"501713"},"PeriodicalIF":1.8,"publicationDate":"2026-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146133367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-03DOI: 10.1016/j.endien.2026.501690
Carlos Ríos Gómez, Alicia Macías Batista, Ignacio García Puente, Laura Esther Guerrero Casanova, Miguel Carnero Gregorio
{"title":"Anaplastic thyroid cancer that responds to treatment with RET inhibitor.","authors":"Carlos Ríos Gómez, Alicia Macías Batista, Ignacio García Puente, Laura Esther Guerrero Casanova, Miguel Carnero Gregorio","doi":"10.1016/j.endien.2026.501690","DOIUrl":"https://doi.org/10.1016/j.endien.2026.501690","url":null,"abstract":"","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":" ","pages":"501690"},"PeriodicalIF":1.8,"publicationDate":"2026-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146120564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.endien.2025.501662
María Sara Tapia-Sanchiz, Miguel Antonio Sampedro-Núñez, Sara Jiménez-Blanco, Begoña Molina-Baena
Short bowel syndrome (SBS) represents one of the central conditions in clinical nutrition, with a complex and challenging management. Teduglutide, an analog of human glucagon-like peptide-2 (GLP-2), is the first approved long-term, non-symptomatic treatment for SBS. We present the case of a 62-year-old woman with SBS who required prolonged home parenteral nutrition (HPN). Following clinical stabilization, teduglutide was initiated, leading to significant clinical and nutritional improvement, including spontaneous closure of enterocutaneous fistulas and a 70% reduction in parenteral nutrition requirements. This allowed for a surgical reconstruction, after which she achieved full enteral autonomy, later developing grade 1 obesity. This case highlights the therapeutic potential of teduglutide as a bridging therapy and the remaining uncertainties regarding its long-term management.
{"title":"3, 2, 1! From GLP-2 to GLP-1 analog over a 10-year journey","authors":"María Sara Tapia-Sanchiz, Miguel Antonio Sampedro-Núñez, Sara Jiménez-Blanco, Begoña Molina-Baena","doi":"10.1016/j.endien.2025.501662","DOIUrl":"10.1016/j.endien.2025.501662","url":null,"abstract":"<div><div>Short bowel syndrome (SBS) represents one of the central conditions in clinical nutrition, with a complex and challenging management. Teduglutide, an analog of human glucagon-like peptide-2 (GLP-2), is the first approved long-term, non-symptomatic treatment for SBS. We present the case of a 62-year-old woman with SBS who required prolonged home parenteral nutrition (HPN). Following clinical stabilization, teduglutide was initiated, leading to significant clinical and nutritional improvement, including spontaneous closure of enterocutaneous fistulas and a 70% reduction in parenteral nutrition requirements. This allowed for a surgical reconstruction, after which she achieved full enteral autonomy, later developing grade 1 obesity. This case highlights the therapeutic potential of teduglutide as a bridging therapy and the remaining uncertainties regarding its long-term management.</div></div>","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"73 1","pages":"Article 501662"},"PeriodicalIF":1.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145640914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.endien.2025.501659
Jordi L. Reverter , Gonzalo Díaz Soto , Tomás Martin , Manuel Gargallo , Marcel Sambo , Iñaki Argüelles , Imaging and Associated Techniques Group of the Spanish Society of Endocrinology and Nutrition
Introduction
Before 2014, few Endocrinology and Nutrition Departments nationwide routinely used cervical ultrasound. Following the training activities promoted by the Thyroid Pathology Imaging Group, it is important to evaluate the current level of implementation of ultrasound and ultrasound-guided techniques in clinical practice.
Material and methods
A structured, self-administered survey was designed and sent electronically to hospitals throughout the country.
Results
Responses were received from a total of 101 hospitals. Ninety-three percent of the departments surveyed reported routine use of ultrasound in clinical practice, with specialized consultations in 71% of cases. Sixty percent performed fine-needle aspiration cytology, and 55% performed staging and follow-up of differentiated thyroid cancer. Among minimally invasive techniques (MIT), 42% of centers perform enolization of thyroid cysts and 12% offer thermal ablation techniques, with radiofrequency being the most commonly used modality. Eighty-six% of professionals have received training through the Applied Imaging Techniques for Thyroid Pathology Group of the SEEN (National Institute of Endocrinology and Nutrition). Currently, 56 centers offer specific ultrasound training for medical residents in the specialty.
Conclusion
Over the last decade, ultrasound has been widely implemented in the Endocrinology and Nutrition Departments affiliated with the SEEN, including the incorporation of ultrasound-guided techniques into routine practice. However, the use of MIT such as thermal ablation is still limited, so it is considered necessary to strengthen both specific training and institutional support to promote its maximum implementation.
{"title":"Implementation of cervical ultrasound and related techniques in endocrinology and nutrition services in Spain. ECOSEEN 2025 study","authors":"Jordi L. Reverter , Gonzalo Díaz Soto , Tomás Martin , Manuel Gargallo , Marcel Sambo , Iñaki Argüelles , Imaging and Associated Techniques Group of the Spanish Society of Endocrinology and Nutrition","doi":"10.1016/j.endien.2025.501659","DOIUrl":"10.1016/j.endien.2025.501659","url":null,"abstract":"<div><h3>Introduction</h3><div>Before 2014, few Endocrinology and Nutrition Departments nationwide routinely used cervical ultrasound. Following the training activities promoted by the Thyroid Pathology Imaging Group, it is important to evaluate the current level of implementation of ultrasound and ultrasound-guided techniques in clinical practice.</div></div><div><h3>Material and methods</h3><div>A structured, self-administered survey was designed and sent electronically to hospitals throughout the country.</div></div><div><h3>Results</h3><div>Responses were received from a total of 101 hospitals. Ninety-three percent of the departments surveyed reported routine use of ultrasound in clinical practice, with specialized consultations in 71% of cases. Sixty percent performed fine-needle aspiration cytology, and 55% performed staging and follow-up of differentiated thyroid cancer. Among minimally invasive techniques (MIT), 42% of centers perform enolization of thyroid cysts and 12% offer thermal ablation techniques, with radiofrequency being the most commonly used modality. Eighty-six% of professionals have received training through the Applied Imaging Techniques for Thyroid Pathology Group of the SEEN (National Institute of Endocrinology and Nutrition). Currently, 56 centers offer specific ultrasound training for medical residents in the specialty.</div></div><div><h3>Conclusion</h3><div>Over the last decade, ultrasound has been widely implemented in the Endocrinology and Nutrition Departments affiliated with the SEEN, including the incorporation of ultrasound-guided techniques into routine practice. However, the use of MIT such as thermal ablation is still limited, so it is considered necessary to strengthen both specific training and institutional support to promote its maximum implementation.</div></div>","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"73 1","pages":"Article 501659"},"PeriodicalIF":1.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145641283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.endien.2025.501657
Stefani Hernández Osorio , María Fátima Garcés , Eva Salazar Alcalá , José Manuel Pestana , Mercedes Fernández Mestre
Objective
This study investigated the association between genetic polymorphisms in the TLR4 (rs4986790 and rs4986791) and IL6 (rs1800795) genes with obesity in a Venezuelan population.
Methods
We conducted a retrospective case-control study with 207 unrelated Venezuelans (137 obese, 70 normal weight). Blood samples were obtained to measure glucose, cholesterol, triglycerides, HDL, insulin, and insulin resistance (HOMA-IR ≥ 2.6) and genotype the TLR4 (rs4986790 and rs4986791) and IL6 (rs1800795) polymorphisms using PCR-SSP. Statistical tests: Student's t-test, Pearson correlation coefficient, chi-square test, odds ratio (OR) with 95%CI were used.
Results
The relationship between obesity and insulin resistance (IR) was confirmed. Heterozygous genotypes A/G (TLR4 rs4986790, P = .012) and C/T (TLR4 rs4986791, P = .005) were more frequent in normal-weight individuals, while homozygous genotypes A/A (TLR4 rs4986790, P = .012) and C/C (TLR4 rs4986791, P = .005) were more frequent in obese individuals. The C allele and CC genotype of IL6 rs1800795 (P = .007) were associated with obesity. The IL6 C/C genotype was associated with higher insulin and HOMA in obese individuals. In obese individuals with IR, the CC genotype (TLR4 rs4986791, P = .03) was more common, as opposted to CT, which was less common (P = .03). The C/C genotype of IL6 rs1800795 was more frequent in obese individuals with IR (P < .0001). Obese individuals with IR and the AA genotype of TLR4 rs4986790 had higher BMI, HOMA-IR, and glucose.
Conclusion
These findings suggest that genetic variations in the TLR4 and IL6 genes may predispose to obesity and its metabolic complications in the Venezuelan population.
目的：本研究探讨了委内瑞拉人群中TLR4 （rs4986790和rs4986791）和IL6 （rs1800795）基因多态性与肥胖的关系。方法：我们对207名委内瑞拉人（137名肥胖，70名正常体重）进行了回顾性病例对照研究。采集血样，测定血糖、胆固醇、甘油三酯、HDL、胰岛素和胰岛素抵抗（HOMA-IR≥2.6），并利用PCR-SSP对TLR4 （rs4986790和rs4986791）和IL6 （rs1800795）多态性进行基因分型。统计学检验：采用学生t检验、Pearson相关系数、卡方检验、比值比（OR）， 95%CI。结果：肥胖与胰岛素抵抗（IR）的关系得到证实。杂合子基因型A/G (TLR4 rs4986790, P =；012)和C/T (TLR4 rs4986791, P =。而纯合子基因型A/A (TLR4 rs4986790, P =。012)和C/C (TLR4 rs4986791, P =。2005)在肥胖人群中更为常见。IL6 rs1800795的C等位基因和CC基因型与肥胖相关（P = 0.007）。在肥胖个体中，IL6 C/C基因型与较高的胰岛素和HOMA相关。在肥胖IR患者中，CC基因型(TLR4 rs4986791, P =。03)较常见，而CT较不常见（P = .03）。il - 6 rs1800795的C/C基因型在肥胖IR患者中更为常见(P结论：这些发现表明，TLR4和il - 6基因的遗传变异可能易导致委内瑞拉人群的肥胖及其代谢并发症。
{"title":"Polymorphisms in TLR4 and IL6 and their association with obesity and insulin resistance in a Venezuelan population","authors":"Stefani Hernández Osorio , María Fátima Garcés , Eva Salazar Alcalá , José Manuel Pestana , Mercedes Fernández Mestre","doi":"10.1016/j.endien.2025.501657","DOIUrl":"10.1016/j.endien.2025.501657","url":null,"abstract":"<div><h3>Objective</h3><div>This study investigated the association between genetic polymorphisms in the <em>TLR4</em> (rs4986790 and rs4986791) and <em>IL6</em> (rs1800795) genes with obesity in a Venezuelan population.</div></div><div><h3>Methods</h3><div>We conducted a retrospective case-control study with 207 unrelated Venezuelans (137 obese, 70 normal weight). Blood samples were obtained to measure glucose, cholesterol, triglycerides, HDL, insulin, and insulin resistance (HOMA-IR ≥ 2.6) and genotype the <em>TLR4</em> (rs4986790 and rs4986791) and <em>IL6</em> (rs1800795) polymorphisms using PCR-SSP. Statistical tests: Student's <em>t</em>-test, Pearson correlation coefficient, chi-square test, odds ratio (OR) with 95%CI were used.</div></div><div><h3>Results</h3><div>The relationship between obesity and insulin resistance (IR) was confirmed. Heterozygous genotypes A/G (<em>TLR4</em> rs4986790, <em>P</em> = .012) and C/T (<em>TLR4</em> rs4986791, <em>P</em> = .005) were more frequent in normal-weight individuals, while homozygous genotypes A/A (<em>TLR4</em> rs4986790, <em>P</em> = .012) and C/C (<em>TLR4</em> rs4986791, <em>P</em> = .005) were more frequent in obese individuals. The C allele and CC genotype of <em>IL6</em> rs1800795 (<em>P</em> = .007) were associated with obesity. The <em>IL6</em> C/C genotype was associated with higher insulin and HOMA in obese individuals. In obese individuals with IR, the CC genotype (<em>TLR4</em> rs4986791, <em>P</em> = .03) was more common, as opposted to CT, which was less common (<em>P</em> = .03). The C/C genotype of <em>IL6</em> rs1800795 was more frequent in obese individuals with IR (<em>P</em> < .0001). Obese individuals with IR and the AA genotype of <em>TLR4</em> rs4986790 had higher BMI, HOMA-IR, and glucose.</div></div><div><h3>Conclusion</h3><div>These findings suggest that genetic variations in the <em>TLR4</em> and <em>IL6</em> genes may predispose to obesity and its metabolic complications in the Venezuelan population.</div></div>","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"73 1","pages":"Article 501657"},"PeriodicalIF":1.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145641285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.endien.2025.501645
Ana M. Díaz Abram , Federico Volpi , Estefanía Chumbiauca , Marta García Goñi , Juan C. Galofré
{"title":"Enhancing levothyroxine dosing accuracy post-total thyroidectomy using body fat percentage","authors":"Ana M. Díaz Abram , Federico Volpi , Estefanía Chumbiauca , Marta García Goñi , Juan C. Galofré","doi":"10.1016/j.endien.2025.501645","DOIUrl":"10.1016/j.endien.2025.501645","url":null,"abstract":"","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"73 1","pages":"Article 501645"},"PeriodicalIF":1.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146001817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.endien.2025.501658
Irene Bretón , José Manuel Fernández García , Nuria Vilarrasa , Violeta Ramírez Arroyo , Ani de Hollanda , Guadalupe Blay Cortés , María D. Ballesteros-Pomar , on behalf of SEEN, SEMERGEN, semFYC and SEMG
Obesity is a chronic, multifactorial and relapsing disease with a great impact on public health. Due to its high prevalence and complications, it is essential to coordinate clinical care in different health care settings in order to improve the clinical evaluation and treatment of people with obesity and to optimize the use of health care resources. This document, prepared by experts from the Spanish Society of Endocrinology and Nutrition (SEEN), the Spanish Society of Primary Care Physicians (SEMERGEN), the Spanish Society of Family and Community Medicine (semFYC) and the Spanish Society of General Practitioners (SEMG) proposes a comprehensive clinical approach to obesity, based on effective coordination between Primary Care and Endocrinology and Nutrition Departments.
{"title":"Continuity of care in obesity clinical care","authors":"Irene Bretón , José Manuel Fernández García , Nuria Vilarrasa , Violeta Ramírez Arroyo , Ani de Hollanda , Guadalupe Blay Cortés , María D. Ballesteros-Pomar , on behalf of SEEN, SEMERGEN, semFYC and SEMG","doi":"10.1016/j.endien.2025.501658","DOIUrl":"10.1016/j.endien.2025.501658","url":null,"abstract":"<div><div>Obesity is a chronic, multifactorial and relapsing disease with a great impact on public health. Due to its high prevalence and complications, it is essential to coordinate clinical care in different health care settings in order to improve the clinical evaluation and treatment of people with obesity and to optimize the use of health care resources. This document, prepared by experts from the Spanish Society of Endocrinology and Nutrition (SEEN), the Spanish Society of Primary Care Physicians (SEMERGEN), the Spanish Society of Family and Community Medicine (semFYC) and the Spanish Society of General Practitioners (SEMG) proposes a comprehensive clinical approach to obesity, based on effective coordination between Primary Care and Endocrinology and Nutrition Departments.</div></div>","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"73 1","pages":"Article 501658"},"PeriodicalIF":1.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145641173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号